NCT04682912

Brief Summary

It is speculated that in adult patients with COVID-19 blood type A is associated with the worst outcome, while blood type O is associated with mild symptoms.To our knowledge, there has been no such a study investigated ABO and Rhesus (Rh) blood group types in children with COVID-19 infection yet. Therefore, the study aimed to examine if such a correlation exists in children infected with COVID-19.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 22, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 24, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

January 30, 2021

Completed
2 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2021

Completed
Last Updated

February 3, 2021

Status Verified

January 1, 2021

Enrollment Period

2 days

First QC Date

December 22, 2020

Last Update Submit

January 30, 2021

Conditions

COVID-19 Infection

Keywords

COVID-19ABO blood groupinfection risk

Outcome Measures

Primary Outcomes (1)

  • Patient medical files

    ABO blood type distribution will be different in COVID-19

    1 month

Eligibility Criteria

Age1 Month - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

A retrospective multicenter trial in five major hospitals in Turkey to determine whether ABO and Rh blood types carry any risk/beneficial factor among children with COVID-19 infection.

You may qualify if:

  • The study period consisted between March 2020 and December 2020
  • Children with a documented positive COVID-19 nasal smear real-time reverse-transcriptase polymerase chain reaction (PCR) assay were included.

You may not qualify if:

  • Patients who had a past medical history of any chronic illness (related to respiratory, cardiology, immunology, neurology, metabolic, etc) were excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mersin City Training & Research Hospital

Mersi̇n, 33240, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Ali̇ Özdemi̇r, MD

    Mersi̇n Şehi̇r Eği̇ti̇m Ve Araşti̇rma Hastanesi̇

    PRINCIPAL INVESTIGATOR

  • Ali̇ Özdemi̇r

    Mersi̇n Şehi̇r Eği̇ti̇m Ve Araşti̇rma Hastanesi̇

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ali̇ Özdemi̇r, MD

CONTACT

03242251000aliozdemir@hotmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc Prof Ali Özdemir

Study Record Dates

First Submitted

December 22, 2020

First Posted

December 24, 2020

Study Start

January 30, 2021

Primary Completion

February 1, 2021

Study Completion

February 1, 2021

Last Updated

February 3, 2021

Record last verified: 2021-01

Locations

TU(1)